News
Novo Nordisk beats on Q1 earnings, cuts 2025 outlook
Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Novo Nordisk trades for ...
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for its U.S. business ...
3h
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
Super Micro Computer’s guidance for its fiscal fourth quarter misses analysts’ estimates, while Advanced Micro Devices top ...
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback